(2007). Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy.
(2007). Blood biomarkers for prostate cancer detection and prognosis.
(2010). Cancer statistics,
(2000). Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer.
(2005). Detection of prostate cancer with a blood-based assay for early prostate cancer antigen.
(2010). Development of ‘‘extended radical retropubic prostatectomy’’: a surgical technique for improving margin positive rates in prostate cancer.
(2004). Early identification of individuals with prostate cancer in negative biopsies.
(2008). Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
(2007). EPCA-2: a highly specific serum marker for prostate cancer.
(2005). Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate.
(1996). Extended followup of the influence of wide excision of the neurovascular bundle(s) on prognosis in men with clinically localized prostate cancer and extensive capsular perforation.
(2010). Increased serum level of early prostate cancer antigen (EPCA) is associated with subsequent cancer risk in men with high grade prostatic intraepithelial neoplasia.
(2008). Individualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels.
(2008). Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.
(1996). Longitudinal screening for prostate cancer with prostate-specific antigen.
(2005). Management of prostate cancer in China: a multicenter report of 6 institutions.
(2004). Mechanisms of androgen-refractory prostate cancer.
(2004). Molecular determinants of resistance to antiandrogen therapy.
(2002). Nadir prostate specific antigen as a predictor of progression to androgen-independent prostate cancer.
(2004). Nadir prostatespecific antigen best predicts the progression to androgen-independent prostate cancer.
(2007). Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy.
(2009). New molecular biomarkers for the prognosis and management of prostate cancer–the post PSA era.
(2005). Nuclear matrix protein expression in prostate cancer: possible prognostic and diagnostic applications.
(1999). Nuclear matrix proteins and their potential applications to diagnostic pathology.
(2000). Nuclear matrix proteins as cancer markers.
(2003). Nuclear matrix proteins changes in cancerous prostate tissues and their prognostic valuein clinically localized prostate cancer.
(2010). Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy.
(2010). Serum early prostate cancer antigen (EPCA) as a significant predictor of incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia.
(2005). The changing face of prostate cancer.
(1998). The Veterans Administrative Cooperative Urologic Research Group
(2006). Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.